Glucagon-like peptide-1 (GLP-1) type obesity drug craze is hot.Demand for Novo Nordisk's Ozempic, Hugo Bee, and Eli Lilly's ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds ...

The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The Lilly Endowment donated $30 million to Scouting America and $2.5 million to the National Juneteenth Museum.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck announces a $2.0 billion agreement with Hansoh Pharma. The deal gives it rights to Hansoh's experimental weight-loss ...

Merck & Co. has secured a licensing agreement with Chinese drugmaker Hansoh Pharma for an experimental oral weight-loss drug, ...

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...